CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. ASH 2015.

Poster

A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-associated Mechanism. ASH 2015.

Poster

SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels. AACR 2015.

Poster

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. ASH 2014.

Poster

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. ASH 2014.

Abstract

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia. ASH 2014.

Abstract